Posterior Reversible Encephalopathy Syndrome Following Chemotherapy and Immune Checkpoint Inhibitor Combination in a Patient with Small-Cell Lung Cancer

被引:3
|
作者
Evin, Cecile [1 ]
Lassau, Nathalie [1 ,2 ]
Balleyguier, Corinne [1 ,2 ]
Assi, Tarek [3 ]
Ammari, Samy [1 ,2 ]
机构
[1] Univ Paris Saclay, Dept Imaging, Gustave Roussy, F-94805 Villejuif, France
[2] Univ Paris Saclay, CNRS, Biomaps, INSERM,CEA,UMR1281, F-94805 Villejuif, France
[3] Univ Paris Saclay, Dept Oncol, Gustave Roussy, F-94805 Villejuif, France
关键词
PRES; chemotherapy; immunotherapy; status epilepticus; diaschisis; LEUKOENCEPHALOPATHY SYNDROME; CARBOPLATIN; IMMUNOTHERAPY;
D O I
10.3390/diagnostics12061369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Posterior reversible encephalopathy syndrome (PRES) is a rare neurological complication that occurs following a sudden blood pressure increase. We report the case of a 64-year-old patient presenting PRES several hours after the administration of a combination of chemotherapy and a checkpoint inhibitor (carboplatin-etoposide-atezolizumab) for small-cell lung cancer. He presented consciousness disorders associated with partial epileptic seizure secondarily generalized. His arterial blood pressure was elevated and brain imaging showed multiple bilateral subcortical parietal, temporal, occipital and cerebellar T2 high signals, predominantly in the posterior region. There were no abnormal T1 signals nor bleeding but a left apparent diffusion coefficient restriction was noted. On arterial spin labelling perfusion sequences, there was an increased perfusion within the left temporo-parieto-occipital, left thalamic and right cerebellar regions. Finally, the neurological symptoms completely regressed after several days of optimal antihypertensive and antiepileptic treatment. The clinical context and radiological features, as well as the progressive resolution of the neurological symptoms, were all in favor of PRES. PRES can occur after the administration of chemotherapy and/or immunotherapy. Prompt diagnosis is crucial through a spectrum of suspicious clinical and radiological characteristics that must be rapidly recognized to quickly anticipate the optimal therapeutic strategy and avoid unnecessary complications.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Opsoclonus-Ataxia Syndrome in a Patient With Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
    Farina, Antonio
    Villagran-Garcia, Macarena
    Benaiteau, Marie
    Lamblin, Florian
    Fourier, Anthony
    Honnorat, Jerome
    Joubert, Bastien
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2024, 11 (05): : e200287
  • [2] Large-vessel vasculitis induced by pegfilgrastim and immune checkpoint inhibitor in a patient with small-cell lung cancer
    Shiraha, Keisuke
    Takigawa, Yuki
    Sato, Akiko
    Fujiwara, Keiichi
    Matsuo, Yuka
    Goda, Mayu
    Inoue, Tomoyoshi
    Nakamura, Eri
    Fujiwara, Miho
    Matsuoka, Suzuka
    Watanabe, Hiromi
    Kudo, Kenichiro
    Sato, Ken
    Shibayama, Takuo
    RESPIROLOGY CASE REPORTS, 2024, 12 (02):
  • [3] Immune Checkpoint Inhibitor-Induced Primary Hyperparathyroidism in a Small-Cell Lung Cancer Patient: A Case Report
    Zhang, Ying
    Cui, Yangang
    Li, Yan
    Cong, Lei
    MEDICINA-LITHUANIA, 2023, 59 (02):
  • [4] Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
    Travert, Camille
    Tomasini, Pascale
    Barlesi, Fabrice
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 401 - 405
  • [5] Combination chemotherapy for relapsed small-cell lung cancer
    Kalemkerian, Gregory P.
    LANCET ONCOLOGY, 2016, 17 (08): : 1033 - 1035
  • [6] LAMBERT EATON MYASTHENIC SYNDROME IN A PATIENT WITH SMALL CELL LUNG CANCER ON IMMUNE CHECKPOINT INHIBITOR THERAPY
    Anderson, Collin
    Guidon, Amanda
    Khan, Farrah
    Riehle, Carolyne
    Kolb, Noah
    MUSCLE & NERVE, 2020, 62 : S47 - S47
  • [7] PARANEOPLASTIC ATAXIA AND ENCEPHALOPATHY IN A PATIENT WITH SMALL-CELL LUNG CANCER
    Mahta, Ali
    Bhavsar, Tapan M.
    NEURO-ONCOLOGY, 2012, 14 : 83 - 83
  • [8] Posterior reversible encephalopathy syndrome (PRES) presenting as intractable vomiting in a patient with metastatic small cell lung cancer on chemoimmunotherapy
    Wood, Katie
    Furlong, William
    Stokoe, Joanna
    LUNG CANCER, 2021, 156 : S77 - S77
  • [9] Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
    Nabet, Barzin
    Hamidi, Habib
    Lee, Myung Chang
    Banchereau, Romain
    Morris, Stefanie
    Adler, Leah
    Gayevskiy, Velimir
    Elhossiny, Ahmed
    Srivastava, Minu
    Patil, Namrata
    Smith, Kiandra
    Jesudason, Rajiv
    Chan, Caleb
    Chang, Patrick
    Fernandez, Matthew
    Rost, Sandra
    Mcginnis, Lisa
    Koeppen, Hartmut
    Gay, Carl
    Minna, John
    Heymach, John
    Chan, Joseph
    Rudin, Charles
    Byers, Lauren
    Liu, Stephen
    Reck, Martin
    Shames, David
    CANCER CELL, 2024, 42 (03) : 429 - 443.e4
  • [10] Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer
    Takeda, Kenichiro
    Miwa, Hideki
    Kono, Masato
    Hirama, Ryutaro
    Oshima, Yuiko
    Mochizuka, Yasutaka
    Tsutsumi, Akari
    Miki, Yoshihiro
    Hashimoto, Dai
    Nakamura, Hidenori
    RESPIRATORY MEDICINE CASE REPORTS, 2023, 42